1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.4. Global Market Value (US$ Mn) Forecast, 2023 – 2033
4.5. Porter’s Five Force Analysis
4.6. Value Chain Analysis
4.7. Market Outlook
5. Global Market Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033
5.4.1. Proton pump inhibitors
5.4.2. H2 Antagonist
5.4.3. Acid neutralizers
5.5. Market Attractiveness By Drug Class
6. Global Market Analysis and Forecasts, By Formulation
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market Value (US$ Mn) Forecast By Formulation, 2023-2033
6.4.1. Tablet
6.4.2. Liquid
6.4.3. Powder
6.4.4. Others
6.5. Market Attractiveness By Formulation
7. Global Market Analysis and Forecasts, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Others
7.5. Market Attractiveness By Distribution Channel
8. Global Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value (US$ Mn) Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East and Africa
8.3. Market Attractiveness By Country/Region
9. North America Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Key Trends
9.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033
9.2.1. Proton pump inhibitors
9.2.2. H2 Antagonist
9.2.3. Acid neutralizers
9.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033
9.3.1. Tablet
9.3.2. Liquid
9.3.3. Powder
9.3.4. Others
9.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Others
9.5. Market Value (US$ Mn) Forecast By Country, 2023-2033
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Class
9.6.2. By Formulation
9.6.3. By Distribution Channel
9.6.4. By Country
10. Europe Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Key Trends
10.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033
10.2.1. Proton pump inhibitors
10.2.2. H2 Antagonist
10.2.3. Acid neutralizers
10.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033
10.3.1. Tablet
10.3.2. Liquid
10.3.3. Powder
10.3.4. Others
10.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Market Value (US$ Mn) Forecast By Country, 2023-2033
10.5.1. U.K.
10.5.2. Germany
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Formulation
10.6.3. By Distribution Channel
10.6.4. By Country
11. Asia Pacific Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Key Trends
11.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033
11.2.1. Proton pump inhibitors
11.2.2. H2 Antagonist
11.2.3. Acid neutralizers
11.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033
11.3.1. Tablet
11.3.2. Liquid
11.3.3. Powder
11.3.4. Others
11.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Market Value (US$ Mn) Forecast By Country, 2023-2033
11.5.1. India
11.5.2. China
11.5.3. Japan
11.5.4. Australia & New Zealand
11.5.5. Rest of Aisa Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Formulation
11.6.3. By Distribution Channel
11.6.4. By Country
12. Latin America Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Key Trends
12.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033
12.2.1. Proton pump inhibitors
12.2.2. H2 Antagonist
12.2.3. Acid neutralizers
12.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033
12.3.1. Tablet
12.3.2. Liquid
12.3.3. Powder
12.3.4. Others
12.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Market Value (US$ Mn) Forecast By Country, 2023-2033
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Formulation
12.6.3. By Distribution Channel
12.6.4. By Country
13. Middle East and Africa Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Key Trends
13.2. Market Value (US$ Mn) Forecast By Drug Class, 2023-2033
13.2.1. Proton pump inhibitors
13.2.2. H2 Antagonist
13.2.3. Acid neutralizers
13.3. Market Value (US$ Mn) Forecast By Formulation, 2023-2033
13.3.1. Tablet
13.3.2. Liquid
13.3.3. Powder
13.3.4. Others
13.4. Market Value (US$ Mn) Forecast By Distribution Channel, 2023-2033
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Others
13.5. Market Value (US$ Mn) Forecast By Country, 2023-2033
13.5.1. South Africa
13.5.2. Saudi Arabia
13.5.3. Rest of MEA
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Formulation
13.6.3. By Distribution Channel
13.6.4. By Country
14. Competition Landscape
14.1. Market Players
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. AstraZeneca
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Business Overview
14.2.1.3. Product Portfolio
14.2.1.4. Financial Overview
14.2.1.5. SWOT Analysis
14.2.1.6. Strategic overview
14.2.2. Bayer AG
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Business Overview
14.2.2.3. Product Portfolio
14.2.2.4. Financial Overview
14.2.2.5. SWOT Analysis
14.2.2.6. Strategic overview
14.2.3. Boehringer Ingelheim GmbH
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2. Business Overview
14.2.3.3. Product Portfolio
14.2.3.4. Financial Overview
14.2.3.5. SWOT Analysis
14.2.3.6. Strategic overview
14.2.4. Dr. Reddy’s Laboratories Ltd.
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2. Business Overview
14.2.4.3. Product Portfolio
14.2.4.4. Financial Overview
14.2.4.5. SWOT Analysis
14.2.4.6. Strategic overview
14.2.5. GlaxoSmithKline plc
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2. Business Overview
14.2.5.3. Product Portfolio
14.2.5.4. Financial Overview
14.2.5.5. SWOT Analysis
14.2.5.6. Strategic overview
14.2.6. Johnson & Johnson
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.6.2. Business Overview
14.2.6.3. Product Portfolio
14.2.6.4. Financial Overview
14.2.6.5. SWOT Analysis
14.2.6.6. Strategic overview
14.2.7. Pfizer Inc.
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.7.2. Business Overview
14.2.7.3. Product Portfolio
14.2.7.4. Financial Overview
14.2.7.5. SWOT Analysis
14.2.7.6. Strategic overview
14.2.8. Procter & Gamble
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Business Overview
14.2.8.3. Product Portfolio
14.2.8.4. Financial Overview
14.2.8.5. SWOT Analysis
14.2.8.6. Strategic overview
14.2.9. Reckitt Benckiser Group plc
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Business Overview
14.2.9.3. Product Portfolio
14.2.9.4. Financial Overview
14.2.9.5. SWOT Analysis
14.2.9.6. Strategic overview
14.2.10. Sanofi
14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.10.2. Business Overview
14.2.10.3. Product Portfolio
14.2.10.4. Financial Overview
14.2.10.5. SWOT Analysis
14.2.10.6. Strategic overview
14.2.11. Sun Pharmaceuticals Ltd
14.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.11.2. Business Overview
14.2.11.3. Product Portfolio
14.2.11.4. Financial Overview
14.2.11.5. SWOT Analysis
14.2.11.6. Strategic overview
14.2.12. Takeda Pharmaceutical
14.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.12.2. Business Overview
14.2.12.3. Product Portfolio
14.2.12.4. Financial Overview
14.2.12.5. SWOT Analysis
14.2.12.6. Strategic overview
14.2.13. Valeant Pharmaceuticals International, Inc.
14.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.13.2. Business Overview
14.2.13.3. Product Portfolio
14.2.13.4. Financial Overview
14.2.13.5. SWOT Analysis
14.2.13.6. Strategic overview
Table 01: Global Market Size (US$ Mn) Forecast, By Drug Class, 2018–2033Table 02: Global Market Size (US$ Mn) Forecast, By Formulation, 2023-2033
Table 03: Global Market Size (US$ Mn) Forecast, By Distribution Channel, 2018–2033
Table 04: Global Market (US$ Mn) Forecast, By Region, 2018–2033
Table 05: North America Market Size (US$ Mn) Forecast, by Drug Class, 2018–2033
Table 06: North America Market Size (US$ Mn) Forecast, by Formulation, 2018–2033
Table 07: North America Market Size (US$ Mn) Forecast, By Distribution Channel, 2018–2033
Table 08: North America Market Size (US$ Mn) Forecast, by Country, 2018–2033
Table 09: Europe Market Size (US$ Mn) Forecast, by Drug Class, 2018–2033
Table 10: Europe Market Size (US$ Mn) Forecast, by Formulation, 2018–2033
Table 11: Europe Market Size (US$ Mn) Forecast, By Distribution Channel, 2018 and 2033
Table 12: Europe Market Size (US$ Mn) Forecast, by Country, 2018–2033
Table 13: Asia Pacific Market Size (US$ Mn) Forecast, by Drug Class, 2018–2033
Table 14: Asia Pacific Market Size (US$ Mn) Forecast, by Formulation, 2018–2033
Table 15: Asia Pacific Market Size (US$ Mn) Forecast, By Distribution Channel, 2018 and 2033
Table 16: Asia Pacific Market Size (US$ Mn) Forecast, by Country, 2018–2033
Table 17: Latin America Market Size (US$ Mn) Forecast, by Drug Class, 2018–2033
Table 18: Latin America Market Size (US$ Mn) Forecast, by Formulation, 2018–2033
Table 19: Latin America Market Size (US$ Mn) Forecast, By Distribution Channel, 2018–2033
Table 20: Latin America Market Size (US$ Mn) Forecast, by Country, 2018–2033
Table 21: Middle East and Africa Market Size (US$ Mn) Forecast, by Drug Class, 2018–2033
Table 22: Middle East and Africa Market Size (US$ Mn) Forecast, by Formulation, 2018–2033
Table 23: Middle East and Africa Market Size (US$ Mn) Forecast, By Distribution Channel, 2018 and 2033
Table 24: Middle East and Africa Market Size (US$ Mn) Forecast, by Country, 2018–2033
| ※参考情報 制酸薬は、胃酸を中和する目的で使用される医薬品です。主に胃や食道において過剰に分泌された胃酸による不快感や痛みを緩和するために用いられます。制酸薬は、一般的には口服薬として摂取されることが多く、様々な形状で提供されています。錠剤、液体、チューブタイプの薬など、利用者の好みに応じた製品が販売されています。 制酸薬の主な種類には、アルミニウム化合物、マグネシウム化合物、カルシウム化合物、およびナトリウム化合物が含まれます。アルミニウム化合物は、胃酸を中和するのに効果的で、消化不良や胃痛に用いられますが、便秘を引き起こすことがあります。マグネシウム化合物は便秘を緩和する効果があり、アルミニウムと組み合わせて使われることが多いです。 カルシウム化合物は、胃酸を中和するだけでなく、骨の健康にも寄与するとされており、カルシウム補給としても利用されることがあります。ただし、大量に摂取すると逆に酸を増加させることがあるため、注意が必要です。ナトリウム化合物は速やかに効果を発揮しますが、高血圧の人には推奨されないことがあります。 制酸薬の主な用途は、胃酸過多による症状の緩和です。特に、胃食道逆流症(GERD)や消化性潰瘍、胃炎などの症状を和らげるために使用されます。これらの状態は、胃酸が食道や胃の内壁を刺激することによって引き起こされ、胸焼けや胃痛などの不快な症状が現れます。そのため、制酸薬はこれらの症状を軽減するために非常に有効な手段となります。 制酸薬を使用する際には、その効果が一時的であることに留意する必要があります。症状が持続する場合や頻繁に起こる場合には、根本的な原因の調査が重要です。また、長期的な使用は、体内の電子バランスや消化吸収に影響を与える可能性があるため、医師の指導のもとでの使用が望まれます。 腸内環境を整えるためのプロバイオティクスや食事療法と併用することで、より健康的な消化を促進することが期待できます。十分な水分摂取や、刺激物を避けることで状況を改善することも可能です。 さらに、制酸薬には製品によって効果の持続時間や作用が異なるため、目的に応じた選択が重要です。例えば、急性の症状を緩和するためには速効性のある製品が望まれ、一方で、長時間の効果を求める場合は持続性のある製品が適しています。 近年では、制酸薬の進化も進んでいます。新たな配合成分や、より効果的な製剤技術が開発され、利用者の利便性を高めることが目指されています。また、制酸薬の安全性についても注目されており、副作用のリスクを低減させるための研究が行われています。 制酸薬は、比較的安全に使用できる薬剤ではありますが、過剰な摂取は避けるべきです。特に特定の疾患をお持ちの方や妊娠中の女性は、事前に医師に相談することが重要です。正しく理解し、適切に使用することで、生活の質を向上させる助けとなるでしょう。以上の内容から、制酸薬は医療現場において不可欠な役割を果たしていることが分かります。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/

